Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have been given an average rating of "Buy" by the eleven research firms that are covering the company, Marketbeat Ratings reports. Eleven research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $31.64.
Several brokerages recently issued reports on PHR. KeyCorp reduced their target price on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Truist Financial raised their target price on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Needham & Company LLC reissued a "buy" rating and set a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Finally, Canaccord Genuity Group cut their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th.
Get Our Latest Report on Phreesia
Insider Activity
In other news, CFO Balaji Gandhi sold 1,827 shares of Phreesia stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $27.46, for a total value of $50,169.42. Following the sale, the chief financial officer now owns 103,591 shares in the company, valued at $2,844,608.86. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Allison C. Hoffman sold 6,024 shares of Phreesia stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $143,672.40. Following the completion of the sale, the general counsel now owns 143,830 shares in the company, valued at approximately $3,430,345.50. This trade represents a 4.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,521 shares of company stock worth $1,225,934 over the last 90 days. 5.50% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Phreesia
A number of institutional investors and hedge funds have recently bought and sold shares of PHR. Johnson Financial Group Inc. boosted its position in Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after acquiring an additional 896 shares during the last quarter. BankPlus Trust Department acquired a new position in Phreesia during the fourth quarter worth about $34,000. Quarry LP boosted its position in Phreesia by 210.9% during the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock worth $71,000 after acquiring an additional 1,923 shares during the last quarter. KBC Group NV acquired a new position in Phreesia during the first quarter worth about $74,000. Finally, Venturi Wealth Management LLC acquired a new position in Phreesia during the fourth quarter worth about $76,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.
Phreesia Stock Performance
Shares of NYSE PHR traded up $0.16 during midday trading on Friday, reaching $25.68. The company had a trading volume of 505,896 shares, compared to its average volume of 445,683. The business's 50-day simple moving average is $25.07 and its 200 day simple moving average is $25.83. The stock has a market cap of $1.53 billion, a P/E ratio of -34.71 and a beta of 0.68. Phreesia has a 1 year low of $17.07 and a 1 year high of $30.53. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02.
Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. During the same quarter last year, the company posted ($0.05) earnings per share. The firm's revenue was up 14.5% compared to the same quarter last year. On average, analysts forecast that Phreesia will post -1.1 earnings per share for the current fiscal year.
About Phreesia
(
Get Free ReportPhreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also

Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.